A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.GLP-1 pills for obesity are closer than ever. 2026 is likely the year that two new oral weight loss drugs will reach patients in the U.S. For some people, pills may serve as a more convenient – and potentially in certain cases cheaper – alternative to today's blockbuster injections.Drugmakers Novo Nordisk and Eli Lilly have ...

公司评级与目标价 - 大和于2025年12月16日将公司股票评级从中性上调至买入 当时股价为1062.71美元 [1] - 美国银行维持买入评级 分析师Jason Gerberry将目标价从1286美元微调至1268美元 调整后目标价较当时约1055美元的股价仍有上行空间 [2] 核心增长驱动与产品管线 - 公司在肥胖症治疗市场取得重大进展 其减肥药物已成为重磅产品并推动收入实现两位数增长 [4] - 公司在注射型GLP-1药物领域处于领导地位 即将于2026年推出的口服GLP-1减肥药Orfoglipron被美国银行视为主要增长动力 其在美国的推出和国际扩张备受期待 [3] - 公司凭借减肥药的成功表现打破了制药股作为安全投资品的传统认知 股价表现更像成长股 今年以来涨幅超过30% [4] 近期股价与市场表现 - 当前股价为1062.71美元 日内上涨3.43%或35.20美元 交易区间在1032.55美元至1065美元之间 [5] - 过去52周股价最高达1111.99美元 最低为623.78美元 [5] - 公司市值约为9546.2亿美元 当日成交量为3,695,377股 [5]

Let's go inside out on this name and weight loss drugs across the space. Joining us now is Tom Kulick, CEO, Strategy Asset Managers. Thank you so much for joining me. >> Thank you. Thank you.Happy holidays. >> Yeah, happy holidays to you as well. Thanks so much for being on the floor with us this morning.Look, um let's talk about Eli Lily. It's been doing some good things lately and it's been rewarded. >> Yes, they they have.So, last week they came out with the results from some of the trials that they have ...

Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.Eli Lilly (LLY 1.78%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy and safety for the two highest doses of its next-generation anti-obesity candidate, retatrutide.The trial showed that a 12 mg weekly injection of retatrutide (the highest evaluated dose) delivered an average of 28.7% reduction in body weight over 68 weeks, along with a decrease in pain from knee art ...

该III期研究旨在评估Eloralintide(四个剂量，皮下注射)对比安慰剂治疗伴2型糖尿病的肥胖或超重受试者 的有效性和安全性。研究的主要终点是第64周体重较基线的百分比变化。 Eloralintide是礼来开发的一款胰淀素受体(AMYR)激动剂，可能通过影响食欲或增加饱腹感来减少热量 摄入。 智通财经APP获悉，12月15日，美国临床试验收录网站显示，礼来(LLY.US)启动了 Eloralintide(LY3841136)的首个III期临床试验(ENLIGHTEN-2)。 ...

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the State Street Health Care Select Sector SPDR ETF ETF (XLV) , a passively managed exchange traded fund launched on December 16, 1998.While an excellent vehicle for long term investors, passively managed ETFs are a popular choice among institutional and retail investors due to their low costs, transparency, flexibility, and tax efficiency.Investor-friendly, sector ETFs provide many options to gain low ris ...

Novo Nordisk A/S (NYSE:NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro.Novo Nordisk’s stock was significantly hit when the company shared headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program, investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.First in May, Novo Nordisk lowered its 2025 sales growth, then again in July, it further trimmed its 2025 guidance. Dur ...

In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.Eli Lilly (LLY +3.44%) is executing very well right now, and Wall Street is aware of that. The stock's price-to-earnings (P/E) ratio of 50 is below its five-year average of 54, but very high on an absolute basis. For reference, the S&P 500 index has a P/E ratio of 28.5. Before you buy shares in Lilly, think about what might happen over the next decade.Why is Eli Lilly doing so well right now?The big story around Eli Lilly is ...

昨日收涨3.38%的礼来(LLY.US)今日美股盘前续涨1.16%，报1074.5美元。消息面上，礼来旗下的实验性 口服减肥药orforglipron的审批进程有望明显提速，最快可能在2026年3月底获得美国食品药品监督管理 局(FDA)的监管决定。根据文件披露，FDA曾考虑将其"加速审评凭证(expedited voucher)"项目下的受理 评估时间，从目前的60天缩短至1周，虽然最终方案调整为两至三周，但仍将显著快于原有流程。(格隆 汇) | O LLY 礼来 | | | --- | --- | | 1062.190↑ +34.680 +3.38% 收盘价 12/15 16:00 美东 | | | 1074.500 + 12.310 +1.16% | 盘前价 12/16 04:10 美东 | | 二 24 24 4 8 8 8 8 8 0 | ● 快捷交易 | | 最高价 1065.000 开盘价 1032.550 成交量 464.84万 | | | 最低价 1032.550 昨收价 1027.510 | 成交额 49.11亿 | | 平均价 1056.447 市盈率 TM 51.97 | 总市值 1万 ...

整理 | GLP1减重宝典内容团队 礼来今日公布其 III 期临床试验 TRIUMPH-4 的积极顶线结果。该研究评估了 retatrutide 两个最高剂量（9 mg 与 12 mg）在无糖尿病 的超重或肥胖成人、合并膝骨关节炎人群中的安全性与疗效，并作为健康饮食和运动的辅助治疗方案。 TRIUMPH-4 是一项全球注册性研究，84% 的受试者基线 BMI ≥35 kg/m²。结果显示，两种剂量的 retatrutide 在所有主要及关键次要终 点上均显著优于安慰剂，在 68 周时实现了大幅体重下降，同时明显改善疼痛与身体功能。 在共同主要终点方面： 平均体重最高下降 28.7%（约 71.2 磅）、 膝关节疼痛评分（WOMAC）最高下降 4.5 分，降幅达 75.8%、 这意味着 retatrutide 不仅显著降低体重，还直接改善了肥胖相关的结构性并发症。 礼来心血管与代谢健康业务总裁 Kenneth Custer 博士表示："肥胖合并膝骨关节炎的患者，往往长期忍受疼痛和活动受限，最终可能不 得不接受关节置换手术。TRIUMPH-4 的结果凸显了 retatrutide 作为首创三重激动剂，在体重、疼痛 ...